Eisai to Distribute Actonel Osteoporosis Treatment for Ajinomoto.Tokyo, Japan, Sept 13, 2005 - (JCNN JCNN Japan Corporate News Network ) - Aventis Pharma, Ajinomoto and Eisai jointly announced on September 12 that the three companies have reached an agreement on the distribution of Actonel Tablet See digitizer tablet and tablet computer. TABLET - A query language. ["Human Factor Comparison of a Procedural and a Non-procedural Query Language", C. Welty et al, ACM Trans Database Sys 6(4):626-649 (Dec 1981)]. 2.5mg, a bisphosphonate agent for treating osteoporosis osteoporosis (ŏs'tēō'pərō`sĭs), disorder in which the normal replenishment of old bone tissue is severely disrupted, resulting in weakened bones and increased risk of fracture; osteopenia . Under the agreement terms, Eisai will distribute Actonel for Ajinomoto, which is licensed to manufacture and sell the agent in Japan, beginning on October 1. Aventis Pharma currently distributes the agent. Actonel, which was launched in the global market in 2000, is currently available in 92 countries worldwide. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion